Analysed EISAI CO LTD (ESALF:OTCMKTS) News Sources
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
08-05-2026
yahoo.com
Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story
09-05-2026
yahoo.com
Biogen Moves Alzheimer’s Drug to Late-Stage Trials. Wall Street Thinks It’s a Mistake.
14-05-2026
yahoo.com
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
15-05-2026
yahoo.com
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
20-05-2026
yahoo.com
What is the current price of EISAI CO LTD (ESALF:OTCMKTS)?
The current price of EISAI CO LTD (ESALF:OTCMKTS) is $28.
EISAI CO LTD (ESALF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of EISAI CO LTD (ESALF:OTCMKTS) since the previous trading day is $-0.7625.
EISAI CO LTD (ESALF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of EISAI CO LTD (ESALF:OTCMKTS) since the previous trading day is -2.651%.
What is the most recent average sentiment score for EISAI CO LTD (ESALF:OTCMKTS)?
The most recent average sentiment score for EISAI CO LTD (ESALF:OTCMKTS) is 60 out of 100.
What is the most recent average sentiment for EISAI CO LTD (ESALF:OTCMKTS)?
The most recent sentiment for EISAI CO LTD (ESALF:OTCMKTS) is .
SEC-8K** Filing Available For EISAI CO LTD (ESALF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.